BRAIN BIOTEC.
BNN.XETRA | Research and experimental development on natural sciences and engineering
Brain Biotech AG, formerly BRAIN AG, is a Germany-based industrial biotechnology company specializing in the discovery and development of novel biological solutions and specialty products. The company operates through two segments: BRAIN Industrial BioSolutions and BRAIN Ingredients & Solutions. The...Show More
Better Health for All
10
BRAIN Biotech's product portfolio includes offerings such as Deucrictibant for Hereditary Angioedema
1
, enzymatic wound cleansing (Aurase®)
2
, natural sugar substitutes
3
, and probiotics
4
, all of which are described as having health benefits. The company also develops enzymes to improve plant-based protein sources
5
, enhancing taste, structure, color, and shelf life of plant-based foods
6
. No products with established negative health outcomes are mentioned in the provided articles.
Fair Money & Economic Opportunity
0
The provided articles for BNN.XETRA (BRAIN BIOTEC) focus on the company's financial health
1
, business strategy
2
, market position within the biotechnology sector
3
, and sustainability reporting
4
. The company is described as an industrial biotechnology company. None of the articles contain specific, concrete data points or information relevant to the ethical value of 'Fair Money & Economic Opportunity', which pertains to financial services, lending practices, and economic inclusion for underserved populations. Therefore, no KPIs under this value can be scored based on the evidence provided.
Fair Pay & Worker Respect
20
The company achieved a Total Recordable Incident Rate (TRIR) of 0.38 per 200,000 hours for FY 2022/23, based on 1 recordable work-related injury and no fatalities.
1
The CEO's total compensation to median employee compensation ratio was 14.37:1 for FY 2022/23.
2
The adjusted gender pay ratio for FY 2022/23 shows disparities, with the lowest ratio being 0.8090 for women in middle management positions compared to men in comparable roles.
3
The voluntary employee turnover rate was 18.07% for FY 2022/23.
4
Fair Trade & Ethical Sourcing
0
No specific data related to fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend is provided in the articles.
1
Honest & Fair Business
10
The company reported zero ethics-related regulatory fines in the past three years, as of the 2023/24 financial year.
1
Four out of five Supervisory Board members are independent, and no conflicts of interest were reported by the Supervisory Board during the 2023/2024 reporting period.
2
Kind to Animals
0
No specific, measurable data was found in the provided articles regarding BNN.XETRA's performance across any of the 'Kind to Animals' KPIs. The articles discuss general industry trends, regulatory changes, or other companies, but do not provide concrete evidence for BNN.XETRA's cruelty-free certifications, alternative testing usage, humane certifications, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, animal testing policy, animal testing volume, innovation investment in animal-free alternatives, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement.
1
No War, No Weapons
0
The company's core business is industrial biotechnology, specializing in solutions for industries such as food, cosmetics, pharmaceuticals, and animal nutrition, indicating no defense or arms-related activities. It has no known exposure to controversial weapons and no defense assets to divest. The company committed to the UN Global Compact in mid-2021.
1
Following the Russian invasion of Ukraine, the company terminated all business relations with Russia.
2
The board has no defense business to oversee.
3
Planet-Friendly Business
-40
BRAIN Biotech AG is not participating in any tracked initiatives, indicating an absence of validated science-based targets.
1
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles to assess BNN.XETRA against any of the KPIs for the ethical value 'Respect for Cultures & Communities'.
1
Information regarding formal partnerships, community reinvestment, cultural appropriation incidents, impact assessment protocols, local employment ratios, grievance mechanisms, cultural preservation investments, local procurement, indigenous suppliers, cultural site protection, social license, charitable giving, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training was not explicitly stated for the company.
2
Safe & Smart Tech
0
BNN.XETRA's privacy policy outlines user rights, including information, correction, and deletion, which aligns with industry-standard user privacy controls.
1
The policy also mentions storage period criteria for data, indicating standard data collection and retention practices.
2
Furthermore, the company's privacy policy explicitly references compliance with GDPR, demonstrating basic adherence to applicable regulations.
3
Zero Waste & Sustainable Products
-30
The company reports a 39% recyclable waste rate for its standard waste.
1
It has implemented numerous waste reduction initiatives, including using pectinase enzymes to convert food waste into side stream products, Promod™ 324L for animal waste protein hydrolysis, and NATUZYM® and DELTA-ZYM® enzymes to maximize raw material conversion and reduce waste in food and bio-ethanol production.
2
Additionally, 240 tons of organic waste from the Cardiff site are continuously delivered to a regional biogas plant for recycling, and used packaging is re-used where possible.
3
The company manages hazardous waste, reporting a total volume of 26.811 tons of hazardous substances, and works with certified waste disposal companies for proper disposal.
4
It also develops green microbial-based mining solutions to replace chemical hazards and uses filter cleaner enzymes to lower chemical utilization and discharge.
5
No severe environmental breaches of regulatory limits were reported in the 2021/2022 base year.
6